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Although the probe at the 3′ end will be 
separated from those at the 5′ end of the 
gene in case of fusion, separation does 
not specifically target the bcr.
Davies et al. designed a cus-
tomized ROS1 break-apart probe 
set made of clones CTD-2314K7 
(chr6: 117,338,338-117,438,446) and 
RP11-59K17 (chr6: 117,448,944-
117,627,275), covering exons 42 
and 43 and sequences flanking the 3′ 
part of the gene, and RP11-623N3 
(chr6: 117,654,640-117,833,020) and 
RP11-117O13 (chr6: 117,830,521-
117,971,596) covering sequences flank-
ing the 5′ part and the first 31 exons and 
a small portion of intron 31 of the gene 
(Fig. 1).5 This construct leaves a 27 kb 
gap in which bcr is located.
These FISH “home-made” probe 
sets differ not only by the BAC clones 
used to build them but also by the dis-
tance between clones, varying from 27 
to 246 kb. In fact, the greater the dis-
tance from bcr, the more likely false 
positives could happen. Indeed, breaks 
could occur outside ROS1 bcr and 
even outside the gene, without fusion 
leading to kinase activation. Also, it 
has been shown that deletion of the 5′ 
region could be associated with a ROS1 
fusion, as it has been reported to happen 
during fusions of other genes such as 
those involving ABL1, MLL.6 In these 
cases, deletion occurs at the breakpoint 
site. Therefore, identifying a deletion of 
RP11-835I21, as used by Rogers et al.1 
and Bergethon et al.,3 does not mean 
that sequences of the 5′ part of ROS1 
were removed.
The diversity in probe design 
could explain, at least partially, the 
discrepancies between IHC and FISH 
results. Home-made probes are a good 
alternative to commercially available 
probes but they have to be designed 
carefully. Interpretation of the results 
requires a good knowledge of the design 
of the probes being used to enable mech-
anisms of the chromosomal and molec-
ular rearrangements to be elucidated.
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In Response:
We thank Uguen et al. for their 
interest in our recently published manu-
script titled Comparison of methods 
in the detection of ALK and ROS1 
rearrangements in lung cancer.1 We 
acknowledge their concerns regard-
ing the use of homemade fluorescent 
in situ  hybridization (FISH) probes 
and the importance of their design. At 
the time that the study was conducted 
there were no commercial ROS1 FISH 
probes available therefore we used the 
home-made ROS1 FISH probe that was 
kindly gifted to us from Translational 
Research Laboratory, Massachusetts 
General Hospital and previously uti-
lized in the study by Bergethon et al.2 
Subsequently, when commercial ROS1 
FISH probes became available, spe-
cifically the Cytocell Aquarius ROS1 
Breakapart FISH Probe (Cambridge, 
UK) and Vysis 6q22 ROS1 Break Apart 
FISH Probe Kit (Des Plaines, IL), we 
repeated the cases which were consid-
ered ROS1 positive or atypical. The 
Cytocell Aquarius ROS1 Breakapart 
FISH Probe showed the same results as 
with the homemade ROS1 FISH probe. 
However, the Vysis 6q22 ROS1 Break 
Apart FISH Probe Kit showed the same 
results for the positive case which con-
tained the break and the atypical case 
(loss of 3′ end) but the two other cases 
defined by loss of the 5′ end using the 
home-made ROS1 FISH probe were 
negative by the Vysis 6q22 ROS1 Break 
Apart FISH Probe Kit. This as antici-
pated and highlighted by Uguen et al. 
show there are differences in FISH sig-
nal patterns that is dependent on probe 
design.
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